v3.26.3
Notes to the unaudited interim condensed consolidated statement of financial position - Investments accounted for using the equity method (Details)
€ / shares in Units, € in Millions
6 Months Ended 12 Months Ended
Feb. 24, 2026
EUR (€)
Jan. 14, 2026
EUR (€)
Sep. 26, 2023
¥ / shares
shares
Sep. 26, 2023
€ / shares
shares
Jun. 30, 2026
EUR (€)
Jun. 30, 2025
Dec. 31, 2025
Investments accounted for using the equity method              
Dilution gain on investment in associate         € 0.3    
Hepalys Pharma, Inc              
Investments accounted for using the equity method              
Group's share in % 13.68% 13.92%     13.68% 15.00% 14.64%
Net proceeds from issuing shares € 0.6 € 1.7          
Dilution gain on investment in associate         € 0.3    
Hepalys Pharma, Inc | Catalys Option Agreement              
Investments accounted for using the equity method              
Option to acquire shares in company, percentage     30.00% 30.00%      
Number of shares acquired in associate | shares     1,500,000 1,500,000      
Purchase of interests in investments accounted for using equity method, price per share | (per share)     ¥ 300 € 1.9